Form 4: Skye Bioscience Director Deborah H. Charych Acquires 35,000 Stock Options
SEC Form 4 Filing
Director Deborah H. Charych acquired 35,000 stock options in Skye Bioscience, Inc. on February 29, 2024.
Summary
- On February 29, 2024, Deborah H. Charych, a director of Skye Bioscience, Inc., acquired 35,000 stock options.
- The options have an exercise price of $14.56 per share.
- The options vest in equal monthly installments over one year, starting February 29, 2024.
- The options expire on March 1, 2034.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of stock option acquisition by a director. The acquisition itself can be seen as a slightly positive signal, but it's not a major event.
Positives
- The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future prospects.
Industry Context
This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.
Stakeholder Impact
- The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 02/29/2024 | Date of transaction: Deborah H. Charych acquired 35,000 stock options. |
| 02/29/2024 | Vesting start date: Options vest in equal monthly installments over one year. |
| 03/01/2034 | Expiration date: Options expire ten years from the grant date. |
| 03/04/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.